Key takeaways
Antidepressants may leave many women in their midlife feeling dismissed or misunderstood.
Hormonal changes can mimic symptoms of depression, leading to misdiagnosis.
Advocacy for comprehensive screening can help identify hormone-related issues in women.
Cross-disciplinary awareness can help prevent misdiagnoses, saving economic costs and improving quality of life.
The cloudiness, the crushing exhaustion, and the sadness that draped everything—even the good days—often begin in the late thirties for many women navigating perimenopause. Visits to a family doctor and then a psychiatrist frequently lead to what so many women hear when their mood shifts and energy crashes: “It’s depression.” Prescriptions for antidepressants are often meant to be the way back to baseline, but months can pass with no light coming through the fog. Many women feel not only trapped by their symptoms but invisible inside a healthcare system that sees only one possible solution.¹⁻⁴
This experience is far from uncommon. Data released by the CDC shows that in the U.S. alone, over 13% of adults take antidepressant medications. Among women aged 40–59, this figure jumps to an astonishing 23%.¹ But what happens when these drugs, so widely prescribed, don’t touch the fatigue, the low mood, or the sleep disturbances? Too often, it becomes a story of one-size-fits-all mental health approaches failing to see the hormone-driven reality of symptoms—something sometimes referred to, pejoratively, as the “misdiagnosis pipeline.”
Misdiagnosis in Midlife: How Hormones Complicate the Picture
A striking number of women entering perimenopause and menopause are first funneled through psychiatric care when their hormones begin to shift. Unlike the visible signs of puberty, the transition through menopause is often silent but profound. Emerging evidence suggests that nearly 60% of women experiencing menopausal symptoms report feeling dismissed or misunderstood by healthcare professionals.²⁻⁴
Too many are quickly diagnosed with anxiety or depression without a single question about their menstrual cycle, hot flashes, or sleep quality.
Medical research suggests that hormonal fluctuations during midlife have a pronounced impact on mood and cognition. In particular, lower levels of estrogen and progesterone are associated with increased risks for depression, anxiety, and difficulty concentrating—symptoms that often overlap with psychiatric disorders.²⁻⁴
Yet primary care doctors and psychiatrists may have minimal training in how menopause presents, especially outside the context of classic hot flashes.
This disconnect leads to a staggering number of women prescribed antidepressants, when, in truth, what’s at play is endocrinological—the body’s shifting hormone landscape. According to a 2023 Lancet Review, as many as two-thirds of perimenopausal women treated for depression report inadequate response to medication, prompting a long cycle of medication switches, dosage increases, and lingering frustration on both sides of the prescription pad.²
The Wake-Up Call: Advocating for Comprehensive Screening
After years of little relief, many women begin to wonder if the situation is more than “depression.” Often, it takes one pointed question—“Do you think it could be your hormones?”—to shift the perspective.
Requesting hormone testing can become a turning point. Finally, the word “perimenopause” enters the conversation. Testing may reveal considerable hormonal changes consistent with perimenopause. For many, it is the first time anyone in healthcare suggests that mood instability, sleepless nights, and overwhelming fatigue could be symptoms—not just psychiatric diagnoses, but part of a broader hormonal picture that includes changes in estrogen, progesterone, and even thyroid hormones.²⁻⁴
Hormone Replacement Therapy (HRT) is not a one-size-fits-all solution and carries its own considerations and risks, but for many women, it opens a new avenue of hope. Within several weeks, the fog begins to lift. Mood stabilizes and energy gradually returns—not because depression was simply “cured,” but because the body is finally getting what it needs.²⁻⁴
A Systemic Issue: The Importance of Cross-Disciplinary Awareness
This realization can be both a relief and a source of frustration. The failure to see depression in midlife as a possible hormonal issue can have deep consequences across health and wellbeing.²⁻⁴
A lack of cross-disciplinary training between psychiatry and endocrinology means that symptoms are often siloed. Data underscores that fewer than 20% of providers report feeling “very comfortable” distinguishing between mood disorders and hormone-related changes, despite mounting calls for better integration.²⁻⁴
The economic costs are considerable. Extended courses of ineffective antidepressants, unnecessary sick leave, and lower workplace productivity cost the U.S. billions. More importantly, women lose months—or years—of quality of life due to inadequate or delayed answers.¹²
Redefining the Patient Journey
The conversation about mood and hormones in midlife needs to start earlier and happen more often. Integrative care that brings psychiatry and hormone medicine into partnership could prevent countless misdiagnoses and unnecessary suffering.²⁻⁴
Some healthcare systems are responding. In the UK, the National Institute for Health and Care Excellence (NICE) recommends that clinicians ask about menstrual status and midlife symptoms during depression assessments.³ In Australia, specific menopause clinics offer psychiatric screening as part of hormone care programs. These models could guide reforms elsewhere, helping women get the full picture from day one.
What’s most important is agency: being empowered to ask more questions and advocate for comprehensive care. When patients and clinicians explore both psychiatric and hormonal causes for new mood symptoms, everyone benefits. It is time to see mood shifts in midlife not merely as a psychiatric problem but as a crossroads—a chance for more nuanced, patient-centered care.²⁻⁴
This article is for informational purposes only and is not medical advice. Always consult your healthcare provider regarding any questions or concerns about your health or treatment options.
References
1. Centers for Disease Control and Prevention. Antidepressant use in the United States, 2015–2018. CDC Data Brief No. 377. Accessed April 24, 2026. https://www.cdc.gov/nchs/products/databriefs/db377.htm
2. The Lancet Psychiatry. Depression and menopause review. 2023. Accessed April 24, 2026. https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(23)00125-3/fulltext
3. National Institute for Health and Care Excellence. Menopause: diagnosis and management. NICE Guideline NG23. Accessed April 24, 2026. https://www.nice.org.uk/guidance/ng23
4. Harvard Health Publishing. Hormones and mood in midlife women. Accessed April 24, 2026.https://www.health.harvard.edu/womens-health/hormones-and-mood-in-midlife-women